Prof. Kypros has revolutionised the field of fetal medicine through his extensive research and medical practice achievements, including introducing intrauterine blood transfusions for fetal anaemia
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
According to the Indian Council of Medical Research (ICMR), there will be an estimated 12 % rise in cancer cases in India in the next five years
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
AOI is the leading cancer hospital chain of South Asia operating 16 cancer hospitals in the region
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Subscribe To Our Newsletter & Stay Updated
